Mediwound Ltd (NASDAQ:MDWD) posted its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by $0.03. Mediwound had a negative return on equity of 148.23% and a negative net margin of 1,776.06%. The firm had revenue of $0.54 million for the quarter, compared to analysts’ expectations of $0.56 million. During the same period last year, the business earned ($0.17) earnings per share. The firm’s revenue for the quarter was up 112.6% on a year-over-year basis.
Mediwound (NASDAQ:MDWD) traded down 0.74% during mid-day trading on Friday, reaching $6.75. The company’s stock had a trading volume of 3,606 shares. The stock’s market cap is $148.03 million. The company has a 50 day moving average of $6.41 and a 200-day moving average of $5.81. Mediwound has a 52-week low of $4.25 and a 52-week high of $8.58.
A number of research analysts have recently commented on the company. Oppenheimer Holdings Inc. set a $10.00 price objective on Mediwound and gave the company a “buy” rating in a report on Monday, May 8th. Zacks Investment Research lowered Mediwound from a “hold” rating to a “sell” rating in a report on Tuesday, February 21st. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $10.75.
Large investors have recently bought and sold shares of the company. Renaissance Technologies LLC raised its position in Mediwound by 1.7% in the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock worth $499,000 after buying an additional 1,300 shares in the last quarter. Citadel Advisors LLC raised its position in Mediwound by 4.5% in the third quarter. Citadel Advisors LLC now owns 33,622 shares of the biopharmaceutical company’s stock worth $259,000 after buying an additional 1,456 shares during the period. Wells Fargo & Company MN raised its position in Mediwound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 8,745 shares during the period. Broadfin Capital LLC raised its position in Mediwound by 19.2% in the fourth quarter. Broadfin Capital LLC now owns 633,102 shares of the biopharmaceutical company’s stock worth $2,899,000 after buying an additional 102,117 shares during the period. Finally, Wellington Management Group LLP raised its position in Mediwound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock worth $14,241,000 after buying an additional 213,745 shares during the period. 27.49% of the stock is currently owned by institutional investors.
Mediwound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for Mediwound Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound Ltd and related companies with MarketBeat.com's FREE daily email newsletter.